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Abstract
Background The effect of renal replacement therapy on drug concentrations in patients with sepsis has not been fully 
elucidated because the pharmacokinetic properties of many antimicrobials are influenced by both pathophysiological and 
treatment-related factors. The aim of this study was to determine meropenem concentrations in patients with sepsis before 
and after the initiation of continuous venovenous hemodialysis with regional citrate anticoagulation (RCA-CVVHD).
Methods The study included 15 critically ill patients undergoing RCA-CVVHD due to sepsis-induced acute kidney injury. 
All participants received 2 g of meropenem every 8 h in a prolonged infusion lasting 3 h. Meropenem concentrations were 
measured in blood plasma using high-performance liquid chromatography coupled with tandem mass spectrometry. Blood 
samples were obtained at six-time points prior to and at six-time points after introducing RCA-CVVHD.
Results The median APACHE IV and SOFA scores on admission were 118 points (interquartile range [IQR] 97–134 points) 
and 19.5 points (IQR 18–21 points), respectively. There were no significant differences in the plasma concentrations of 
meropenem measured directly before RCA-CVVHD and during the first 450 min of the procedure. The drug concentration 
reached its peak 2 h after initiating the infusion and then steadily declined.
Conclusions The concentration of high-dose meropenem (2 g every 8 h) administered in a prolonged infusion was similar 
before and after the introduction of RCA-CVVHD in patients with sepsis who developed acute kidney injury.
Keywords Continuous venovenous hemodialysis · Meropenem · Regional citrate anticoagulation · Sepsis · Therapeutic 
drug monitoring
Introduction
Optimal antibiotic dosing is crucial in the therapeutic process, 
especially in critically ill patients with sepsis. These patients 
are at a significantly higher risk of antibiotic underdosing 
due to pathophysiological changes associated with large fluid 
shifts, resulting in an increased volume of distribution, altera-
tions in both renal and liver clearance, as well as decreased 
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concentrations of plasma proteins [1, 2]. Acute kidney injury 
(AKI) is a common life-threatening complication of sepsis, 
which often requires an introduction of continuous renal 
replacement therapy (CRRT).
Meropenem displays time-dependent antibacterial activity, 
that is, its efficacy is associated with the percentage of time 
in which the free drug concentration exceeds the minimum 
inhibitory concentration (MIC), referred to as %fT>MIC [3]. 
The drug has been shown to exert bacteriostatic effects at an 
 fT>MIC of 20% and bactericidal effects at an  fT>MIC of 40% [4]. 
However, the latest evidence on patients with sepsis undergo-
ing CRRT suggests that clinicians should aim at an  fT>MIC of 
100% [5]. Antibacterial activity of meropenem may be maxi-
mal when the antibiotic concentration exceeds the MIC for 
the specific type of bacteria four- to five-fold for the entire 
duration of the dosing interval [6].
The degree of antibiotic clearance varies depending on the 
physicochemical and pharmacokinetic properties of the drug 
[7]. Hydrophilic antibiotics, including carbapenems, have a 
small volume of distribution, low molecular weight, and are 
bound to proteins to a minimal degree, which facilitates their 
rapid elimination during CRRT [8, 9]. However, their phar-
macokinetic properties are known to be influenced by extra-
corporeal blood purification procedures, including CRRT. 
Moreover, an additional use of anticoagulation required for 
CRRT may cause unpredictable drug interactions [10]. Drug 
concentrations may also vary depending on the type of solute 
removal during CRRT (e.g., diffusion, convection), proper-
ties of the semipermeable membrane of the filter, the rate of 
ultrafiltration, as well as the dose of dialysis. Finally, drug 
clearance is also influenced by CRRT settings and the patient’s 
demographic and clinical characteristics, including age, urine 
output, and countercurrent dialysate flow rates [11].
Several authors have suggested that drug doses should be 
carefully adjusted based on its blood concentration [12]. Con-
tinuous renal replacement therapy with regional citrate anti-
coagulation (RCA-CRRT) is becoming increasingly widely 
used in the management of critically ill patients with AKI [13]. 
However, there are no evidence-based recommendations on 
the dosing of drugs commonly used in patients with severe 
sepsis and septic shock treated with RCA-CRRT. Therefore, 
we aimed to assess whether there are significant differences 
in the plasma concentrations of meropenem administered in 
a prolonged infusion before and during RCA-CRRT among 
patients with sepsis who developed AKI.
Materials and methods
Patients
This prospective observational cohort study was conducted 
in the Intensive Care Unit (ICU) at University Hospital in 
Krakow, Poland, between January 2014 and January 2017. 
All procedures involving human participants were conducted 
in accordance with the ethical standards of the institutional 
and national research committees as well as with the 1964 
Helsinki Declaration and its later amendments or compara-
ble ethical standards. The study was approved by the Bioeth-
ics Committee of Jagiellonian University (ul. Grzegórzecka 
20, Kraków; protocol number, KBET/262/B/2013; date of 
approval, 27 January 2014).
This report conforms to the STROBE guidelines; the 
checklist with specific pages where each requirement was 
addressed can be found in Supplementary Table 1.
The inclusion criteria were as follows: (1) age older than 
35 years and younger than 85 years; (2) diagnosis of severe 
sepsis or septic shock (according to the criteria of the Sur-
viving Sepsis Campaign Consensus) [14]; (3) clinical indica-
tions for CRRT due to AKI, determined in accordance with 
the criteria adopted by Kidney Disease Improving Global 
Outcomes (KDIGO) recommendations: hyperkalemia 
(serum potassium concentration > 6.5 mmol/L or rapidly ris-
ing), refractory fluid overload, metabolic acidosis, and signs 
of uremia (such as pericarditis or encephalopathy) [15]; (4) 
use of regional citrate anticoagulation (RCA) during CRRT; 
and (5) treatment with high doses of meropenem (2 g every 
8 h) in prolonged infusions (lasting 3 h).
The exclusion criteria were lack of patient consent, preg-
nancy, bilirubin concentrations exceeding 150 μmol/L, blood 
transfusion of more than 50% of the circulating volume in 
the past 8 h, and the use of other extracorporeal techniques 
(such as plasmapheresis) in the past 24 h.
Methods
Patients’ medical records were analyzed and relatives were 
interviewed to obtain demographic and clinical data such 
as age, sex, weight, height, comorbidities, site of infection, 
and laboratory parameters at baseline and during CRRT (i.e., 
complete blood count, coagulation parameters, serum con-
centrations of creatinine, urea, bilirubin, albumin, total pro-
tein, levels of inflammatory biomarkers including C-reactive 
protein, and procalcitonin).
The severity of clinical condition was assessed with 
the Acute Physiology and Chronic Health Evaluation 
(APACHE) IV score on admission and the Sequential Organ 
Failure Assessment (SOFA) score on the 1st, 3rd, and 7th 
day of ICU stay.
Continuous renal replacement therapy
Continuous renal replacement therapy was initiated accord-
ing to the local practice and study protocol. Continuous 
venovenous hemodialysis with RCA (RCA-CVVHD) was 
used. The main indications for CRRT were metabolic 
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acidosis, oliguria with fluid overload, and hyperkalemia. 
For CRRT, commercially available equipment and solu-
tions were used:  MultiFiltrate® with the integrated Ci-Ca® 
system, 1.8-m2 capillary hemofilters  Ultraflux® AV 1000S 
with membrane Fresenius  Polysulfone®, Dialysate K2 or K4 
(Fresenius Medical Care, Bad Hamburg, Germany). Antico-
agulation was performed using 4% trisodium citrate (citrate 
flow rates were subsequently adjusted based on postfilter 
ionized calcium levels) and calcium chloride solution  (CaCl2 
flow rates were based on calcium levels measured in arterial 
blood).
All CRRT settings (timing, modality, intensity of dialy-
sis, RCA) were identical for each participant at the begin-
ning of the procedure and were subsequently adapted to the 
patient’s clinical status in accordance with KDIGO recom-
mendations (blood flow 120–150 mL/min; dialysate flow 
rate 2000–3450 mL/h; patient fluid removal [ultrafiltration], 
0 in the first hour, and then 100 mL/h and higher according 
to clinical condition) [11]. The CRRT intensity was calcu-
lated as an effluent flow rate (dialysate rate [mL/h] + ultra-
filtrate [mL/h]/weight [kg]). Regarding the CRRT settings, 
the median intensity at baseline was 31.4 mL/kg/h (range 
25–35 mL/kg/h), and the median blood flow was 124 mL/
min (range 120–150 mL/min). All CRRT settings, includ-
ing dialysate rate, ultrafiltrate rate, blood flow, as well as 
 CaCl2 and citrate solution flow rates, were recorded for each 
participant.
Meropenem dosing
Meropenem was administered intravenously through a 
separate lumen of a central venous catheter in a prolonged 
infusion, according to the dosing schedule identical for all 
patients (2 g in 3-h infusion administered every 8 h). Each 
dose was reconstituted in 50 mL of 0.9% sodium chloride.
Blood sampling
Blood samples for each patient were collected at specified 
time points before the drug administration and then at 30, 60, 
90, 120, 180, and 450 min after meropenem infusion. The 
first set of samples was collected around the time of the first 
meropenem infusion after the decision on the introduction 
of RCA-CVVHD was made based on the above criteria for 
patients with sepsis. Subsequently, on the same day, RCA-
CVVHD was initiated according to local practice by the ICU 
personnel. The second set of samples was collected when the 
first meropenem infusion was given during RCA-CRRT. For 
each sample, 2 mL of blood was collected from an arterial 
catheter. Samples were centrifuged at 3500 rpm for 10 min 
at 4 °C and stored at − 80 °C until further analysis.
The study timeline is shown in Fig. 1.
Meropenem measurements
The measurement of plasma meropenem concentrations 
was performed in the Department of Molecular Biology 
and Clinical Genetics of Jagiellonian University Medi-
cal College. The concentrations of unbound drug were 
measured using high-performance liquid chromatography 
(Prominence, Shimadzu, Tokyo, Japan) coupled with tan-
dem mass spectrometry (Qtrap 4000, AB Sciex, Toronto, 
Canada). The tris buffer (0.2 mL) and chemically identi-
cal deuterated internal standard meropenem-d6 (5 μg) were 
added to plasma (0.2 mL). The sample was extracted with 
the mixture of tert-butyl methyl ether and methanol (4:1, 
v:v) twice. An organic layer was collected and evaporated 
under the stream of nitrogen. After evaporating the solvent, 
the residue was reconstituted in mobile phase (30 μl). Chro-
matography separation was performed using Zorbax Eclipse 
XDB C-18 column (1 × 50 mm, 3 μm) (Agilent, Santa Clara, 
CA, USA) and mobile phases consisting of water–formic 
acid (100:0.1%) and acetonitrile–methanol–formic acid 
(50:50:0.1%) to gradient elution. Meropenem was measured 
using the multiple reaction monitoring in the positive ioni-
zation mode, monitoring transition m/z 384 > 141 and m/z 
384 > 68 for meropenem and m/z 390 > 147 and m/z 390 > 68 
for deuterated meropenem-d6. Meropenem concentrations 
were determined using a calibration curve in the range of 
0.05–250 μg/mL (r2 = 0.997) [16, 17].
Statistical analysis
Dependent quantitative variables were compared using the 
paired Student t test or the Wilcoxon test for matched pairs 
depending on the distribution of the difference between two 
variables. Observed correlations were analyzed using a lin-
ear mixed model. Confidence intervals and p values were 
calculated using the likelihood ratio method. The normality 
assumption was examined using the Shapiro–Wilk test.
The level of 0.05 was assumed as significant. The analysis 
was carried out using the R software, version 3.4.1. (R Foun-
dation for Statistical Computing, Vienna, Austria).
Results
The study included 15 eligible patients (mean age, 
57.8 ± 7.5 years; five women, ten men) with sepsis or septic 
shock who received meropenem and RCA-CVVHD. Base-
line demographic and clinical characteristics of the patients 
are shown in Table 1.
All patients were mechanically ventilated due to respira-
tory failure, and 13 patients (87%) required vasopressors. 
The median APACHE IV and SOFA scores were 118 points 
(interquartile range [IQR] 97–134 points) and 19.5 points 
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(IQR 18–21 points), respectively. The mean predicted mor-
tality rate for the APACHE IV and SOFA scores was 68.6% 
and > 90%, respectively.
Respiratory tract infection was the most common cause of 
sepsis (73%; 11 patients), followed by urinary tract infection 
(27%; four patients). Bloodstream infection was confirmed 
in four cases (27%; four patients). The pathogen for sepsis 
was identified in 13 cases (87%): Gram-positive bacteria 
in five cases (Staphylococcus aureus, vancomycin-resistant 
enterococci, coagulase-negative staphylococci) and Gram-
negative bacteria in 8 cases (Acinetobacter baumannii, Pseu-
domonas aeruginosa, Klebsiella pneumoniae, Citrobacter 
freundii, and Escherichia coli). Data concerning infection 
sites and pathogens are shown in Table 2.
Analysis of meropenem concentrations
We did not find significant differences in meropenem con-
centrations measured before and during CRRT at any time 
point after drug infusion (Table 3). The drug concentration 
in plasma reached its peak 2 h after the start of the infusion 
and then steadily declined, as shown in Fig. 2. Moreover, 
there were no statistically significant differences in mero-
penem concentrations measured before and during CRRT 
at any time point after drug infusion among patients with 
anuria (66.7%; ten patients) and those with residual diuresis 
(33.3%; 5/patients). Among the five patients with available 
MIC for meropenem, the concentrations were 0.25 μg/mL 
or less in four cases (66.7%) and 0.125 μg/mL in two cases 
(33.3%). The number of measurements in which plasma 
meropenem concentrations exceeded the respective hypo-
thetical MICs before and during RCA-CRRT is shown in 
Table 4.  
Discussion
In this prospective observational study including 15 patients 
with sepsis-induced AKI, we found that prolonged infusions 
of meropenem resulted in similar concentrations of the drug 
before and after the initiation of CRRT.
Critically ill patients presenting with severe sepsis or sep-
tic shock are at higher risk of receiving insufficient doses 
of antimicrobials due to increased volume of distribution, 
hypoalbuminemia, as well as altered renal and nonrenal 
clearance [8]. To improve outcomes in this challenging 
population, it is crucial to achieve proper antibiotic concen-
trations. Several authors have suggested that the antibiotic 
concentration should be systematically measured in these 
patients and titrated accordingly [18]. It is particularly com-
plicated in the context of severe sepsis or septic shock with 
concomitant AKI requiring CRRT. In a study by Economou 
et al. [19], the antibiotic dose had to be adjusted in 35% of 
critically ill patients undergoing CRRT in whom therapeutic 
Fig. 1  Flow chart of the study 
timeline showing the time of 
meropenem administration and 
use of continuous venovenous 
hemodialysis with regional 
citrate anticoagulation (RCA-
CVVHD). †End of infusion. 
Dotted area represents the time 
of meropenem infusion
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drug monitoring (TDM) was performed [19]. Unfortunately, 
TDM is rarely available in ICUs worldwide; thus, the appro-
priateness of antibiotic dosing usually remains uncertain.
Previous studies evaluating meropenem concentrations 
during CRRT, based on pharmacokinetic models and simu-
lations, have reported conflicting results [20, 21]. Moreover, 
these discrepancies were related not only to dosing but also 
to the administration method (continuous infusion versus 
intermittent bolus administration; 30 min versus 3 h) [22, 
23]. The recommended dose for such patients ranges from 
500 mg every 12 h to 2 g every 8 h. In this study, we decided 
to use the latter dose due to the high prevalence of multid-
rug-resistant bacteria, high ultrafiltration and dialysate flow 
rates, as well as the presence of the abovementioned factors 
inherent in patients with sepsis that reduce plasma concen-
trations of the antibiotic [24]. Another difficulty is asso-
ciated with the largely unpredictable influence of various 
Table 1  Baseline demographic 
and clinical characteristics of 
the study group
APACHE IV Acute Physiology and Chronic Health Evaluation IV, ARDS acute respiratory distress syn-
drome, BMI body mass index, SOFA sequential organ failure assessment
Characteristic Value
Age (years); mean (SD) 57.8 (7.5)
Male sex; n (%; 95% CI) 10 (66.7%; 38.7–87.0%)
Body weight (kg); mean (SD) 81 (8.6)
BMI (kg/m2); mean (SD) 27.5 (3.2)
APACHE IV score; median (IQR) 118 (97–134)
Day 1 SOFA score; median (IQR) 19.5 (18–21)
Day 3 SOFA score (12/15 patients); median (IQR) 20.5 (17–23)
Day 7 SOFA score (10/15 patients); median (IQR) 18.5 (16.3–21)
Organ dysfunction, n (%; 95% CI)
 Respiratory (ARDS) 15 (100%; 74.7–100%)
 Renal 15 (100%; 74.7–100%)
 Cardiovascular 11 (73.3%; 44.8–91.1%)
 Hematologic 10 (66.7%; 38.7–87.0%)
 Central nervous system 2 (13.3%; 2.3–41.6%)
 Liver 2 (13.3%; 2.3–41.6%)
Medication, n (%; 95% CI)
 Vasopressors 13 (86.7%; 58.4–97.7%)
 Mechanical ventilation 15 (100%; 74.7–100%)
Laboratory results
 White blood cell (× 109/L); mean (SD) 10.9 (4.2)
 Serum albumin (g/dL); mean (SD) 25.5 (3.1)
 Baseline serum creatinine (µmol/L); mean (SD) 138.5 (41.3)
 Pre-CRRT serum creatinine (µmol/L); mean (SD) 235.7 (52.1)
 Preserved diuresis; n (%; 95% CI) 5 (33.3%; 9.5–57.2%)
 Volume of diuresis (mL/24 h); median (IQR) 162.5 (300–900)
ICU survivors; n (%; 95% CI) 8 (53.3%; 27.4–77.7%)
CRRT settings
 Blood flow rate (mL/min); mean (SD) 124 (5.8)
 Dialysate flow rate (mL/h); median (IQR) 2400 (2000–2700)
 Ultrafiltrate (mL/h); median (IQR) 100 (50–100)
Table 2  Infection events in the study group
Site of infection Value
Respiratory tract; n (%; 95% CI) 11 (73.3%; 44.8–91.1%)
Urinary tract; n (%; 95% CI) 4 (27%; 8.9–55.2%)
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modalities of CRRT on antibiotic concentrations. Some 
studies have shown that β-lactam clearance can vary at least 
partially depending on the CRRT modality [25]. Finally, 
little is known about the effect of anticoagulation used for 
CRRT and antibiotic concentrations.
The RCA-CVVHD is gaining popularity in the routine 
management of critically ill patients [13]. However, the 
recommendations on dosing of widely used medications 
among patients with severe sepsis and septic shock treated 
with RCA-CRRT are lacking. Therefore, we decided to 
determine the effect of RCA-CVVHD on meropenem con-
centrations in patients with AKI treated in the ICU due 
to severe sepsis or septic shock. Our patients had high 
median APACHE IV and SOFA scores indicating critical 
condition, thus making them suitable candidates for RCA 
according to KDIGO recommendations [15]. Initial CRRT 
intensity was identical for all patients and was consistent 
with KDIGO recommendations. Moreover, administration 
of an identical dose of meropenem in all patients as well 
as fixed dosing before CRRT and in the first hours after 
its initiation provided a well-suited setting for the assess-
ment of differences in drug concentrations associated with 
RCA-CVVHD. We did not find any differences between 
the plasma concentrations of meropenem before RCA-
CVVHD and in the first 450 min of the procedure. Our 
results suggest that antibiotic dose adjustment might not be 
Table 3  Meropenem 
concentrations (µg/mL) in blood 
before and during continuous 
renal replacement therapy
Continuous variables are expressed as median and interquartile range (Q1, 25th percentile and Q3, 75th 
percentile)
CRRT continuous renal replacement therapy
*Significant p value (< 0.05); paired Student t test or the Wilcoxon test for matched pairs depending on the 
distribution of the difference between two variables
Time point CRRT N Median Min Max Q1 Q3 p value*
(0) Before 15 8.8 0.1 38.7 3.15 17.05 0.359
During 15 11.9 2.7 32.4 6.65 20.65
(1) 30 min Before 15 15 4.3 48.6 7.35 25.2 0.169
During 15 19.4 6.2 48.4 16.2 21.85
(2) 60 min Before 15 18.2 5.3 53 12.25 29.6 0.151
During 15 24.4 9.3 46.8 19.25 37
(3) 90 min Before 15 23.2 13.2 49.3 16.45 32.2 0.389
During 15 27.1 11.1 43.1 24.35 34.4
(4) 120 min Before 15 23.7 15.1 62 19.95 36.7 0.804
During 15 31.1 12.2 41.5 20.2 36.15
(5) 180 min Before 15 24.9 2 60.6 18.7 35.65 0.847
During 15 27.6 10.7 52.4 18.1 34.4
(6) 450 min Before 15 15.4 2.9 52.4 7.28 22.85 0.064
During 14 10.9 1.8 30.6 7.75 14.8
Fig. 2  Meropenem concentra-
tion before and during continu-
ous renal replacement therapy 
(CRRT). Dots and whiskers 
represent median and interquar-
tile range, respectively
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necessary while using RCA-CVVHD, particularly shortly 
after its initiation, which is contradictory to an observed 
tendency to reduce doses recommended for CRRT in this 
period [18]. Our observations also cast doubt on the use 
of TDM in the first hours after the introduction of RCA-
CVVHD and suggest that high doses of meropenem can 
be safely administered. To our knowledge, there have been 
no similar prospective studies evaluating the influence of 
RCA-CVVHD on meropenem concentrations in patients 
with severe sepsis or septic shock.
We are aware of several important limitations of our 
study. First, the study group was relatively small, but at the 
same time, it was very homogeneous as it consisted of crit-
ically ill patients with severe sepsis or septic shock with 
very high predicted mortality according to commonly used 
scoring systems for the severity of illness in critical care. 
Second, we did not measure meropenem concentrations in 
the time points exceeding the prespecified 450 min. Such a 
measurement would allow us to evaluate the effect of filter 
lifespan during the procedure. Also, we did not measure 
meropenem concentrations in urine, ultrafiltrate, and at the 
site of infection. The lack of these measurements limited 
our ability to calculate several significant pharmacokinetic 
variables. Finally, the study group was heterogenous in 
terms of residual diuresis, a factor that influences drug 
clearance.
Conclusion
Plasma concentrations of high-dose meropenem (2 g every 
8 h) administered in a prolonged infusion were similar 
before and after the initiation of RCA-CVVHD.
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 5/7 15 (100%) 15 (100%) 15 (100%) 15 (100%) 15 (100%) 14 (93.3%) 10 (66.7%)
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154 I. Nowak-Kózka et al.
1 3
Ethics approval and consent to participate The study protocol was 
approved by the Jagiellonian University Bioethics Committee (No. 
KBET/262/B/2013).
Consent for publication All authors have reviewed and approved the 
manuscript for publication.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, 
Ferrer R, et al. Surviving sepsis campaign: international guide-
lines for management of sepsis and septic shock: 2016. Intensive 
Care Med. 2017;43(3):304–77. https ://doi.org/10.1007/s0013 
4-017-4683-6.
 2. Blot SI, Pea F, Lipman J. The effect of pathophysiology on phar-
macokinetics in the critically ill patient—concepts appraised 
by the example of antimicrobial agents. Adv Drug Deliv Rev. 
2014;77:3–11. https ://doi.org/10.1016/j.addr.2014.07.006.
 3. Drusano GL. Antimicrobial pharmacodynamics: critical interac-
tions of ‘bug and drug’. Nat Rev Microbiol. 2004;2(4):289–300. 
https ://doi.org/10.1038/nrmic ro862 .
 4. Nicolau DP. Pharmacodynamic optimization of beta-lactams in 
the patient care setting. Crit Care. 2008;12(Suppl 4):S2. https ://
doi.org/10.1186/cc681 8.
 5. Burger R, Guidi M, Calpini V, Lamoth F, Decosterd L, Robatel C, 
et al. Effect of renal clearance and continuous renal replacement 
therapy on appropriateness of recommended meropenem dosing 
regimens in critically ill patients with susceptible life-threatening 
infections. J Antimicrob Chemother. 2018;73(12):3413–22. https 
://doi.org/10.1093/jac/dky37 0.
 6. Jacobs A, Taccone FS, Roberts JA, Jacobs F, Cotton F, Wolff 
F, et  al. β-Lactam dosage regimens in septic patients with 
augmented renal clearance. Antimicrob Agents Chemother. 
2018;62(9):e02534–e2617. https ://doi.org/10.1128/AAC.02534 
-17.
 7. Onufrak NJ, Forrest A, Gonzalez D. Pharmacokinetic and 
pharmacodynamic principles of anti-infective dosing. Clin 
Ther. 2016;38(9):1930–47. https ://doi.org/10.1016/j.clint 
hera.2016.06.015.
 8. Shaw AR, Chaijamorn W, Mueller BA. We underdose antibiotics 
in patients on CRRT. Semin Dial. 2016;29(4):278–80. https ://doi.
org/10.1111/sdi.12496 .
 9. Sinnollareddy MJ, Roberts MS, Lipman J, Roberts JA. Beta-
lactam pharmacokinetics and pharmacodynamics in critically ill 
patients and strategies for dose optimization: a structured review. 
Clin Exp Pharmacol Physiol. 2012;39(6):489–96. https ://doi.org
/10.1111/j.1440-1681.2012.05715 .x.
 10. Valtonen M, Tiula E, Backman JT, Neuvonen PJ. Elimination of 
meropenem during continuous veno-venous haemofiltration and 
haemodiafiltration in patients with acute renal failure. J Antimi-
crob Chemother. 2000;45(5):701–4.
 11. Roberts DM, Roberts JA, Roberts MS, Liu X, Nair P, Cole L, et al. 
Variability of antibiotic concentrations in critically ill patients 
receiving continuous renal replacement therapy. Crit Care Med. 
2012;40(5):1523–8. https ://doi.org/10.1097/CCM.0b013 e3182 
41e55 3.
 12. Wong G, Sime FB, Lipman J, Roberts JA. How do we use thera-
peutic drug monitoring to improve outcomes from severe infec-
tions in critically ill patients? BMC Infect Dis. 2014;14:288. https 
://doi.org/10.1186/1471-2334-14-288.
 13. Schilder L, Nurmohamed SA, Bosch FH, Purmer IM, den Boer 
SS, Kleppe CG, et al. Citrate anticoagulation versus systemic 
heparinisation in continuous venovenous hemofiltration in criti-
cally ill patients with acute kidney injury: a multi-center ran-
domized clinical trial. Crit Care. 2014;18(4):472. https ://doi.
org/10.1186/s1305 4-014-0472-6.
 14. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal 
SM, Surviving Sepsis Campaign Guidelines Committee includ-
ing the Pediatric Subgroup, et al. Surviving sepsis campaign: 
international guidelines for management of severe sepsis and 
septic shock: 2012. Crit Care Med. 2013;41(2):580–637. https 
://doi.org/10.1097/CCM.0b013 e3182 7e83a f.
 15. Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, 
Goldstein SL, Kidney Disease: Improving Global Outcomes 
(KDIGO) Acute Kidney Injury Work Group, et al. KDIGO clini-
cal practice guideline for acute kidney injury. Kidney Int Suppl 
(2011). 2012;2(1):1–138. https ://doi.org/10.1038/kisup .2012.1.
 16. Huang L, Haagensen J, Verotta D, Lizak P, Aweeka F, Yang K. 
Determination of meropenem in bacterial media by LC-MS/MS. 
J Chromatogr B Analyt Technol Biomed Life Sci. 2014;961:71–
6. https ://doi.org/10.1016/j.jchro mb.2014.05.002.
 17. Kameda K, Ikawa K, Ikeda K, Morikawa N, Nakashima A, 
Ohge H, Sueda T. HPLC method for measuring meropenem 
and biapenem concentrations in human peritoneal fluid and bile: 
application to comparative pharmacokinetic investigations. J 
Chromatogr Sci. 2010;48(5):406–11.
 18. Ulldemolins M, Vaquer S, Llauradó-Serra M, Pontes C, Calvo 
G, Soy D, Martín-Loeches I. Beta-lactam dosing in critically 
ill patients with septic shock and continuous renal replacement 
therapy. Crit Care. 2014;18(3):227. https ://doi.org/10.1186/
cc139 38.
 19. Economou CJP, Wong G, McWhinney B, Ungerer JPJ, Lipman 
J, Roberts JA. Impact of β-lactam antibiotic therapeutic drug 
monitoring on dose adjustments in critically ill patients under-
going continuous renal replacement therapy. Int J Antimicrob 
Agents. 2017;49(5):589–94. https ://doi.org/10.1016/j.ijant imica 
g.2017.01.009.
 20. Jaruratanasirikul S, Thengyai S, Wongpoowarak W, Wattanavi-
jitkul T, Tangkitwanitjaroen K, Sukarnjanaset M, et al. Popula-
tion pharmacokinetics and Monte Carlo dosing simulations of 
meropenem during the early phase of severe sepsis and septic 
shock in critically ill patients in intensive care units. Antimi-
crob Agents Chemother. 2015;59(6):2995–3001. https ://doi.
org/10.1128/AAC.04166 -14.
 21. Dhaese SAM, Farkas A, Colin P, Lipman J, Stove V, Verstraete 
AG, et al. Population pharmacokinetics and evaluation of the 
predictive performance of pharmacokinetic models in critically 
ill patients receiving continuous infusion meropenem: a com-
parison of eight pharmacokinetic models. J Antimicrob Chem-
other. 2019;74(2):432–41. https ://doi.org/10.1093/jac/dky43 4.
 22. Jamal JA, Mat-Nor MB, Mohamad-Nor FS, Udy AA, Wallis 
SC, Lipman J, Roberts JA. Pharmacokinetics of meropenem 
in critically ill patients receiving continuous venovenous hae-
mofiltration: a randomised controlled trial of continuous infu-
sion versus intermittent bolus administration. Int J Antimicrob 
155Concentration of meropenem in patients with sepsis and acute kidney injury before and after…
1 3
Agents. 2015;45(1):41–5. https ://doi.org/10.1016/j.ijant imica 
g.2014.09.009.
 23. Vardakas KZ, Voulgaris GL, Maliaros A, Samonis G, Fala-
gas ME. Prolonged versus short-term intravenous infusion 
of antipseudomonal β-lactams for patients with sepsis: a sys-
tematic review and meta-analysis of randomised trials. Lancet 
Infect Dis. 2018;18(1):108–20. https ://doi.org/10.1016/S1473 
-3099(17)30615 -1.
 24. Tamatsukuri T, Ohbayashi M, Kohyama N, Kobayashi Y, 
Yamamoto T, Fukuda K, et al. The exploration of population 
pharmacokinetic model for meropenem in augmented renal 
clearance and investigation of optimum setting of dose. J Infect 
Chemother. 2018;24(10):834–40. https ://doi.org/10.1016/j.
jiac.2018.07.007.
 25. Jamal JA, Mueller BA, Choi GY, Lipman J, Roberts JA. How 
can we ensure effective antibiotic dosing in critically ill 
patients receiving different types of renal replacement therapy? 
Diagn Microbiol Infect Dis. 2015;82(1):92–103. https ://doi.
org/10.1016/j.diagm icrob io.2015.01.013.
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
